Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review

Table 1

Review of ibrutinib therapy for patients with LPD and CNS involvement.

Ref.	Age	Sex	Diagnosis	Prior lines	CNS therapy	FU	Response	DOR	Toxicity
[11]	61	M	MCL	3	Ibrutinib 560 mg	12 m	CR	Ongoing	None
[11]	62	M	MCL	2	Ibrutinib 560 mg	9 m	CR	Ongoing	None
[11]	77	F	MCL	2	Ibrutinib 560 mg	2 m	PR	Ongoing	None
[12]	54	M	MCL	1	HD-MTX and HiDAC + Ibrutinib 560 mg/d	4 m	PR	4 m	Bruising
[12]	55	M	MCL	1	Ibrutinib 560 mg MP 500 mg 4 d	5 m	PR	4 m	None
[12]	65	M	MCL	1	Ibrutinib 560 mg Dexamethasone IT Cytarabine	4 m	CR	Ongoing	None
[12]	58	M	MCL	1	Ibrutinib 560 mg	5 m	PR	Ongoing	None
[12]	57	M	MCL	1	HD-MTX; Ibrutinib 560 mg	1 w	Transient PR	6 d	None
[13]	58	M	CLL	8	HiDAC, MTX, oxaliplatin, R- monotherapy, IT-CT, Iv immunoglobulins → Ibrutinib 420 mg/d	9 m	CR	9 m	Atrial fibrillation → death (stroke)
[13]	65	M	CLL	4		14 m	CR	Ongoing	None
[13]	63	M	CLL	2		8 m	CR	Ongoing	None
[13]	68	F	CLL	0		9 m	CR	Ongoing	None
[14]	66	M	CLL	0	Ibrutinib 420 mg/d	8 m	CR	Ongoing	None
[15]	72	M	WM/BNS	1	R, HD-MTX; IT liposomal cytarabine → Ibrutinib 420 mg/d	6 m	CR	Ongoing	None
[15]	56	M	WM/BNS	1	R-HiDAC → Ibrutinib	6 m	CR	Ongoing	None

DOR: duration of response; MP: methylprednisolone; HD-MTX: high-dose methotrexate; HiDAC: high-dose ARA-C; IT-CT: intrathecal chemotherapy; m: months; w: week; d: days.